79 results about "Hematologic disease" patented technology

Various thienopyrimidine-based analog compounds are able to selectively inhibit the Src family of tyrosine kinases. These compounds are useful in the treatment of various diseases including hyperproliferative diseases, hematologic diseases, osteoporosis, neurological diseases, autoimmune diseases, allergic / immunological diseases, or viral infections.

The present invention provides a humanized anti-human CD34 antibody and the preparation method thereof. The humanized anti-human CD34 antibody retains the affinity and specificity of its original murine-derived antibody. The antibody can be conjugated with magnetic nano materials to prepare immunomagnetic beads to screen marrow hemopoietic stem cells. It can effectively reduce the incidence rate of HAMA and improve the security of clinical transplantation of hemopoietic stem cells and can be used in treatment of certain malignant hematologic diseases and solid tumors.

Methods, systems, and computer readable media are provided for processing microscopic images of a biological sample from a patient. One or more images of a blood sample from a microscope is obtained, each image comprising a plurality of different types of cells. The one or more images are processed by a machine learning system to classify individual cells into one of a plurality of cell categories. The cells in each cell category are analyzed to determine characteristics of the respective cell category. A diagnosis or list of possible diagnosis are determined based on the classification and characteristics of the cells for the patient in an automated manner.

The invention relates to a segregation device and method of multidirectional continual blood component, which comprises the following steps: gathering blood by gathering needle (10); pushing the blood to the centrifugal container (12, 30) through the pipe route; setting the external blood flow process pipe system in the multidirectional centrifugal rotary device in connection with blood flow path pipe (6) by several control pumps (1); setting the centrifugal container in the rotational hemisphere (16) of centrifugal rotary device. The driving shaft (33) between rotational hemisphere and centrifugal rotary device is fixed to rotate with rotational hemisphere along its own orbital trace. The device transmits the signal from color comparator sensor (4) to corresponding control system after multidirectional centrifugal separating, which shortens the gathering blood time to improve the gathering rate of blood component and is applied in the clinical blood pathological component separation or improves the clinical curative effect in displacement therapy.

The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.

A method for modulating hematopoietic stem cells and treating a hematologic disease in a mammal comprising administering intranasally a therapeutically effective amount of a PTH formulation. The PTH formulation may contain teriparatide.

The present invention relates to an ozonized compound containing an olefin double bond, specifically to ozone addition of a compound containing an olefin double bond. According to the present invention, the obtained ozonized compound containing the olefin double bond prevents and treats infectious diseases, autoimmune diseases, ischemic diseases, retinal degenerative diseases, skin diseases, lungdiseases, kidney diseases, hematologic diseases, neurodegenerative diseases, cancer, orthopedic surgical diseases, back pains, chronic fatigue syndromes, trauma / burn and emergency surgery, surgery andorgan transplantation, and prolapse of intervertebral disc through an oral route.

The invention provides a blood virus RAN protective agent and a blood sampling tube. The blood virus RAN protective agent is prepared by dissolving the following components in DEPC (diethyl pyrocarbonate) solution 100-500mg / ml glycine, 1-5mg / ml aprotinin, 1-5mg / ml wortmannin, 10-40mg / ml glutathione, 100-500mg / ml sodium thiocyanate, 1-3mg / ml anticoagulant and 5-20mg / ml membrane protective agent. The blood virus RAN protective agent provided by the invention is capable of supplying long-term protection to virus RNA in blood under room temperature, preventing degradation and pollution of virus RNA and effectively guaranteeing accuracy and validity of blood sample.

The present invention relates to pathogen inactivator composition for blood or blood component for clinical transfusion and its compounding process. The blood pathogen inactivator consists of photosensitizer capable of inactivating blood or blood component and supplementary material for venoclysis in the weight of 2-10 times that of the photosensitizer. The pathogen inactivator in the pathogen inactivator composition is solid and has the stability of the pathogen inactivating photosensitizer maintained. The pathogen inactivator and relevant supplementary material is prepared through high temperature pyrogen eliminating and abacterial filtering, and may be used in the photochemical pathogen inactivation of blood or blood component.

The invention relates to a precisely controllable gripper apparatus for low force applications. A system and a method are for quantifying blood loss on the basis of contrast-agent based computed tomography imaging of the torso of a patient. To this end, image data of a computed tomograph is firstly read in, in order thereupon to apply an image analysis method (2) for automatically detecting accumulations of blood. A differentiation method (3) is then carried out to differentiate between pathological and physiological accumulations of blood and a quantification algorithm (4) for calculating andoutputting (5) a blood loss value for the pathological accumulations of blood.

Preparation of an orally administrable pharmaceutical composition containing traditional Chinese medicine for hematologic diseases is disclosed. The pharmaceutical composition is for immunotherapy and is made from natural, non-toxic medicinal materials through extraction and other preparing processes. The pharmaceutical composition is helpful to prevent, mitigate and cure cancers.

This invention relates to an enriched population of isolated and expanded human cord blood stem cells and a method of producing an enriched population of isolated and expanded human cord blood stem cells. The expanded human cord blood stem cells are CD34+, CD90+, CD1 84+, CD1 17+, CD49f+, ALDH+, CD45RA− and express pluripotency genes SOX2, OCT4, NANOG, and ZIC3. In one embodiment, the stem cells in the enriched population of the present invention are positive for aldehyde dehydrogenase activity (ALDH+). In addition, in one embodiment the expanded stem cells are nearly depleted of T cells and B cells and contain a limited number of monocytes (CD14). Also disclosed is a method of treating a subject for a hematological disorder using the stem cells of the present invention and a method of determining the effects of a compound on hematopoietic stem cells.

A reconstituted polypeptide characterized by inducing apoptosis in nuclear blood cells having integrin associated protein (IAP) without causing the agglutination of erythrocytes. This reconstituted polypeptide contains at least two H chain V domains and at least two L chain V domains of a monoclonal antibody which induces apoptosis in nuclear blood cells having IAP. This reconstituted polypeptide is useful as a remedy for blood diseases such as leukemia.

The invention discloses a blood disease leukocyte scatter diagram similarity analysis method based on structural analysis, and belongs to the technical field of blood cell classification. The method comprises the following steps: extracting cell counting results and leukocyte scatter diagrams of various blood diseases detected by a hematology analyzer, carrying out artificial staining microscopicexamination to confirm the types of the blood diseases, carrying out classified storage according to the types of the blood diseases, and constructing a training set; comparing the leukocyte scatter diagrams of each category in the training set through a structural similarity analysis algorithm to obtain similarity; analyzing the similarity to obtain a characteristic leukocyte scatter diagram anda similarity range of each type of blood diseases, and taking the characteristic leukocyte scatter diagram as an original image; the to-be-detected image detected by the hematology analyzer is compared through the original image and the similarity range of each type of blood diseases, automatic classification of images collected by the hematology analyzer is achieved, and the effect of quickly andaccurately analyzing and classifying leukocyte scatter diagrams of the blood diseases is achieved.

The invention relates to a hot-drinking plaster preparation used for curing blood platelet countpenia of endogenous heat due to yin deficiency type, which comprises medicinal materials such as India madder roots, rehmannia root, common anemarrhena rhizome, amur corktree bark, glossy privet fruit, eclipta, red paeony root, charred radix scutellariae, fresh oyster, couchgrass roots, lotus rhizome node, ass-hide glue, tortoise plastron, common yam rhizome, etc. The hot-drinking plaster preparation of the invention used for preventing and curing blood platelet countpenia of endogenous heat due to yin deficiency type and has the advantages and effects of rich raw materials, easy preparation, convenient dosing, strong targeting force and guiding force, good treatment effect, no toxic and side effect, has one hundred percent of efficiency for clinically curing the blood platelet countpenia of endogenous heat due to yin deficiency type, etc., which fills the blank of a task field of processing the hot-drinking plaster preparation with the treatment functions of nourishing the kidney, producing medulla, nourishing yin, clearing away the lung-heat, eliminating pathogenic heat from the blood, activating blood circulation to dissipate blood stasis, dispelling heat from blood to stop bleeding, nourishing yin and suppressing hyperactive yang and proliferating blood platelet and greatly develops research on medicine culture of food therapy of human hematologic disease nowadays.

The invention relates to a medicament for treating hematuria and a preparation method thereof. The medicament is prepared from raw yam, raw fossil fragments, raw oyster, cuttlebone, madder, radices paeoniae alba, the root of Chinese pulsatilla, donkey-hide gelatin and gentian according to certain parts by weight through compatibility. The Chinese medicinal composition disclosed by the invention can replenish and nourish blood, clear away heat and remove toxicity, resist bacteria and inflammation, moisturize dryness and stop bleeding, promote blood coagulation and improve compactness of the vascular wall and has a practical curative effect of treating hematuria caused by tumors of the urinary system, prostatitis, acute cystitis, acute nephritis and kidney or ureteral calculus and particularly hematuria caused by blood diseases. Moreover, the medicament has no toxic or side effects.

The invention discloses a blood genome DNA extraction method based on a 3D printed special-shaped functional body and an application kit thereof, and belongs to the field of nucleic acid extraction and separation. According to the method, a sample is subjected to a cracking treatment by using a cracking solution, and nucleic acid combination, separation and purification are carried out by using a3D printed special-shaped functional body, the 3D printed functional body is quickly transferred in a cracking solution, a cleaning solution and an eluent in a handheld or mechanical holding mode, time-consuming and tedious steps such as liquid transferring and centrifuging are not needed, the manual labor density is low, the cost is low, the flux is high, the quality of obtained nucleic acid is high, the requirement for equipment and operation space is small, and the method has automation and high-flux downstream application prospects. Furthermore, the invention also provides an application kit of the blood genome DNA extraction method. The invention solves the problems of complex preparation of target nucleic acid, time consumption, and low flux in an existing PCR in-vitro amplificationtechnology and the method has wide application prospects in rapid detection of blood pathogens.

The invention relates to the field of biotechnology. Hematopoietic stem cell transplantation is a unique way of curing malignant hematologic diseases, but the complications in the hematopoietic stem cell transplantation process are still key factors causing death of the patient, and the most prominent is graft-versus-host disease (FVHD). How to prevent and treat the GVHD is a severe challenge to hematopoietic stem cell transplantation. The invention provides an adenovirus vector carrying inducible co-stimulater (ICOS) gene, and a construction method for the adenovirus vector. After the adenovirus vector transfects mesenchymal stem cells (MSCs), an aim of preventing and treating the GVHD is fulfilled by a method of combining the effect of the ICOS in the T lymphocyte activating process and the effect of the MSCs in the immune adjusting process.

New monoclonal antibodies for use in pre-treatments prior to stem cell transplantations are disclosed. The antibodies may be used to kill malignant cells and / or stem cells prior to stem cell transplantation. The antibodies can be used for treating hematologic diseases and hematological malignancies, such as leukemia and MDS. The antibodies of the invention might be multi- or bi-specific, such as BiTEs.

The present invention relates to ozonized vitamins, specifically to ozone addition of vitamin A, vitamin D and vitamin C. According to the present invention, the obtained ozonized vitamins prevent andtreat infectious diseases, autoimmune diseases, ischemic diseases, retinal degenerative diseases, skin diseases, lung diseases, kidney diseases, hematologic diseases, neurodegenerative diseases, cancer, orthopedic surgical diseases, back pains, chronic fatigue syndromes, trauma / burn and emergency surgery, surgery and organ transplantation, and prolapse of intervertebral disc through an oral route.

The invention discloses a device for detecting a blood disease fusion gene. The device comprises a sequencing module used for obtaining sequencing data of a tumor sample through next-generation sequencing; a data preprocessing module used for preprocessing the sequencing data obtained in the sequencing module; a candidate k-mers identification module used for identifying candidate k-mers possiblycomprising breakpoints in the sequencing data processed by the data preprocessing module; a local assembly comparison recognition fusion mode module used for extracting reads where a candidate k-mersset of the tumor sample is located and paired reads, and carrying out local assembly to obtain contigs; a fusion gene credibility prediction module used for predicting the fusion gene credibility; anda fusion result annotation module used for annotating the breakpoints obtained in the fusion gene credibility prediction module. By applying the technical scheme provided by the invention, various fusion variation types of multiple genes can be accurately identified.

The invention discloses a molecular marker and an application thereof in detection of vascular immunoblastic T cell lymphoma, and belongs to the technical field related to blood disease detection. According to the application, a combination of multiple markers disclosed by the invention is applied to flow cytometry detection of vascular immunoblastic T cell lymphoma and / or monitoring of minimal residual focuses. The molecular marker disclosed by the invention can be widely applied to living cell samples such as bone marrow, peripheral blood, lymph nodes, puncture objects, skin tissues, pleural effusion, peritoneal effusion and the like of a patient, the combination of various markers is effectively arranged, abnormal cells of AITL can be quickly screened out in an early stage, the sensitivity and specificity to tissue samples reach 100%, the use amount of cells is small, and operation is rapid, simple and convenient. Meanwhile, for a patient subjected to chimeric antigen receptor T cell treatment, the composition disclosed by the invention can also be used for evaluating the immunofluorescence intensity of an antigen target spot, the immunofluorescence intensity is an indispensable part in cell treatment, and subsequent residue monitoring is not influenced by treatment.

The invention discloses a skin cleaner for hematopoietic stem cell transplantation for blood diseases and relates to the technical field of medical cleaning equipment. The skin cleaner comprises a base, wherein a cleaning solution placement tank is fixedly connected with the upper surface of the base. According to the skin cleaner for hematopoietic stem cell transplantation for the blood diseases, through arranging an electromotor, a rotating shaft I, a rotating shaft II, a bevel gear I, a bevel gear II, a gear I, a gear II, a residual gear, a limiting block, a limiting lever and a connecting column, a cleaning cotton fixing block can be driven to continuously perform horizontal reciprocating movement in a back and forth direction, then, a cleaning process for the surface of skin of a sufferer is achieved under the action of arranged cleaning cotton, and the workload of medical personnel is reduced; and through arranging a miniature water pump, a pumping pipe, a telescopic hose I, a flow diversion member, a telescopic hose II, a hard pipe and an atomization sprayer, a cleaning solution inside the cleaning solution placement tank can be sprayed to the surface of the skin of the sufferer, and then, the skin of the sufferer can be cleaned under the matching of the cleaning cotton.